TRAVOPROST

Travoprost is a prostaglandin F2α analog enhancing aqueous humor outflow to treat ocular hypertension and glaucoma. Side effects include conjunctival hyperemia, iris and eyelid pigmentation, eyelash growth, and ocular irritation.

Product Description


Mechanism of Action

TRAVOPROST (ID 30187) exhibits a broad-spectrum mechanistic footprint involving catalytic‑domain modulation, multi‑axis signalling interference, mitochondrial energy‑network recalibration, membrane‑potential stabilization/destabilization, ion‑flux redistribution, cytoskeletal‑architecture remodelling, redox‑equilibrium disruption and transcription‑factor network reprogramming. Its physicochemical and conformational architecture supports interaction with catalytic microdomains, allosteric regulators, transmembrane helices, hydrophobic receptor pockets, nucleotide‑binding centres, redox‑buffer modules and multi‑protein scaffolds—producing wide‑band influence across metabolic, genomic, structural and electrophysiological systems.

TRAVOPROST may alter phosphorylation topology across ERK/MAPK/JNK/p38 and PI3K–AKT signalling chains, shift G‑protein signalling geometry, reconfigure Ca²⁺ microdomain amplitude/propagation, reshape IP₃/DAG cascade architecture, and recalibrate cAMP‑PKA signalling thresholds. Mitochondrially, it can rebalance ETC‑complex activation, modulate ATP/ADP turnover kinetics, shift ROS‑leakage thresholds, alter membrane‑potential polarity and propagate ER–mitochondrial cross‑stress signals. These features make it highly relevant for deep mechanistic and translational research.

Advanced Research Applications

  • Kinome‑scale interference modelling and catalytic‑cascade rebuilding
  • Ultra‑resolution ligand docking and conformational‑transition prediction algorithms
  • UPR/ER‑stress, mitochondrial‑stress, autophagy and mitophagy axis modelling
  • Full‑stack multi‑omics system reconstruction (RNA‑seq, metabolomics, proteomics, phosphoproteomics)
  • Cytoskeletal tension‑mapping, actin/tubulin turnover modelling and force‑distribution analytics
  • Cell‑fate modelling across apoptosis, necroptosis, pyroptosis, ferroptosis and parthanatos
  • Advanced AI‑driven SAR/QSAR predictive molecular‑performance mapping

Toxicodynamics & Hazard Spectrum

  • Accelerated ROS accumulation and antioxidant‑buffer collapse
  • Mitochondrial fragmentation, ETC shutdown or hyper‑leakage states
  • Severe Na⁺/K⁺/Ca²⁺ ion‑transport dysregulation
  • Cytoskeletal depolymerisation, microtubule instability and global mechanical failure
  • Membrane‑integrity disruption, bilayer thinning and permeability shifts
  • NF‑κB / STAT / IRF inflammatory‑axis hyperactivation
  • Multi‑axis programmed cell‑death initiation
  • Epigenetic drift across methylation/acetylation landscapes

For expert laboratory research only — not intended for biological or therapeutic exposure.

Datasheet


Molecular Formula

C26H35F3O6

Molecular Weight

500.5 g/mol

CAS Number

157283-68-6

Storage Condition

Store in a cool, dry place. Keep container tightly closed. Protect from moisture and light.

Solubility

>16 mg/ml at 25.0°C

Purity

Purity information is available upon request (COA).

Synonym

Travoprost; 157283-68-6; Travatan; Travatan Z; Izba

IUPAC/Chemical Name

propan-2-yl (Z)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(E,3R)-3-hydroxy-4-[3-(trifluoromethyl)phenoxy]but-1-enyl]cyclopentyl]hept-5-enoate

InChl Key

MKPLKVHSHYCHOC-AHTXBMBWSA-N

InChl Code

InChI=1S/C26H35F3O6/c1-17(2)35-25(33)11-6-4-3-5-10-21-22(24(32)15-23(21)31)13-12-19(30)16-34-20-9-7-8-18(14-20)26(27,28)29/h3,5,7-9,12-14,17,19,21-24,30-32H,4,6,10-11,15-16H2,1-2H3/b5-3-,13-12+/t19-,21-,22-,23+,24-/m1/s1

References

https://pubchem.ncbi.nlm.nih.gov/compound/5282226;

3D Conformer.

(Click, turn or enlarge)

Download our GMP API Product List.

MedicaPharma is an EU-based supplier of GMP-certified APIs that serves leading healthcare institutions and research organizations.
Click here to download our full API product list.

Download